Overview

Intratumorally-Administered Topotecan Using CED in High Grade Glioma Undergoing Stereotactic Biopsy

Status:
Withdrawn
Trial end date:
2018-11-19
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if treatment with topotecan by an alternative method, direct delivery into brain tumors, is safe and well tolerated. The Cleveland Multiport Catheter is a new, investigational device that will be used to deliver topotecan into your brain tumor. A second purpose of this study is to determine whether the Cleveland Multiport Catheter can be used effectively and safely to deliver topotecan into your brain tumor. This study will also determine the best dose of topotecan to deliver to your tumor with use of the Cleveland Multiport Catheter and will also examine how your tumor responds to treatment with topotecan.
Phase:
Early Phase 1
Details
Lead Sponsor:
Michael Vogelbaum, MD, PhD
Collaborator:
Infuseon Therapeutics, Inc.
Treatments:
Topotecan